Anti-phospholipid IgG antibodies detected by line immunoassay differentiate patients with anti-phospholipid syndrome and other autoimmune diseases

Table 3 Receiver-operating characteristics curve analysis of anti-phospholipid antibodies (aPL) detected by enzyme-linked immunosorbent assay (ELISA) and line immunoassay (LIA) in 34 patients with anti-phospholipid syndrome and 41 disease controls

aPL	AUC	SE	95% CI
ELISA
aD1/aD4–5	0.760	0.0597	0.647–0.851
aβ₂GPI IgG	0.705	0.0617	0.588–0.805
aβ₂GPI IgM	0.534*,^$,§	0.0679	0.416–0.651
aCL IgG	0.725	0.0598	0.609–0.821
aCL IgM	0.559*,^$,§	0.0679	0.440–0.674
LIA
aβ₂GPI IgG	0.691	0.0638	0.574–0.793
aCL IgG	0.660	0.0651	0.541–0.765
aPS IgG	0.716^&	0.0613	0.600–0.814
aPG IgG	0.723^&	0.0630	0.608–0.821
aPT IgG	0.701	0.0628	0.584–0.801

Area under the curve (AUC) was determined for the ratio of anti-domain 1 of beta₂ glycoprotein I (aD1) and domains 4–5 (D4–5) antibody reactivity (D4–5) by ELISA and compared with those for criteria aPL determined by ELISA and aPL IgG by LIA
aβ₂GPI anti-beta₂ glycoprotein I, aCL anti-cardiolipin, aPG anti-phosphatidyl-glycerol, aPI anti-phosphatidylinositol, aPS anti-phosphatidyl-serine, aPT anti-prothrombin, CI confidence interval, SE standard error
AUC comparison of ELISA
*p < 0.05 for the comparison to the AUC of the ratio of aD1 to D4–5
^$p < 0.05 for the comparison to the AUC of aβ₂GPI IgG
^§p < 0.05 for the comparison to the AUC of aCL IgG
AUC comparison of LIA
^&p < 0.05 for the comparison to the AUC of aCL IgG

ISSN: 2038-3274